Business
Bioventix Announces License Agreement
Bioventix Announces License Agreement.
About this update from Bioventix Plc
[{"type":"text","content":"\n \n Bioventix plc \n\n (\"Bioventix\" or the \"Company\") \n\n Bioventix Announces License Agreement \n\nThe Company has signed a license agreement with DIAsource ImmunoAssays S.A. of\nBelgium (\"DIAsource\") in relation to certain intellectual property owned by\nDIAsource.\n\nIn April 2014, the Company announced that it was taking action to oppose\nDIAsource's European patent in the field of anti-vitamin D antibodies and their\nuse in assays (i.e. tests) for vitamin D sufficiency and deficiency. This\npatent is within the scope of the license which DIAsource has granted to the\nCompany and hence it will cease potentially to restrict Bioventix's business. \nThe license features reasonable commercial terms and Bioventix will withdraw\nthe opposition to the European patent.\n\nPeter Harrison, CEO of Bioventix plc said \"We considered the costs of a\npotential dispute together with the impact of on-going uncertainty on customers\nand shareholders and concluded that a license agreement with DIAsource was the\npreferred outcome. With the license agreement now signed, Bioventix's business\nis no longer potentially restricted by DIAsource's European patent.\"\n\nFor further information please contact:\n\nBioventix plc Chief Executive Officer Tel: 01252 728 001 \nPeter Harrison \n \nfinnCap Ltd Corporate Finance Tel: 020 7220 0500 \nGeoff Nash/Simon Hicks Corporate Broking \nSteve Norcross \n \n\nAbout Bioventix plc:\n\nBioventix (www.bioventix.com) specialises in the development and commercial\nsupply of high-affinity monoclonal antibodies with a primary focus on their\napplication in clinical diagnostics, such as in automated immunoassays used in\nblood testing. The antibodies created at Bioventix are generated in sheep and\nare of particular benefit where the target is present at low concentration and\nwhere conventional monoclonal or polyclonal antibodies have failed to produce a\nsuitable reagent. Bioventix currently offers a portfolio of antibodies to\ncustomers for both commercial use and R&D purposes, for the diagnosis or\nmonitoring of a broad range of conditions, including heart disease, cancer,\nfertility, thyroid function and drug abuse. Bioventix currently supplies\nantibody products and services to the majority of multinational clinical\ndiagnostics companies. Bioventix is based in Farnham, UK and its shares are\ntra...